Company Quick10K Filing
Health-Right Discoveries
Price-0.00 EPS-0
Shares23 P/E0
MCap-0 P/FCF-0
Net Debt5 EBIT-1
TEV5 TEV/EBIT-3
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-03-31 Filed 2020-05-13
10-K 2019-12-31 Filed 2020-03-30
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-16
10-K 2018-12-31 Filed 2019-04-12
10-Q 2018-09-30 Filed 2018-11-09
10-Q 2018-06-30 Filed 2018-08-13
S-1 2018-05-08 Public Filing
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-04-17
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-02
10-Q 2017-03-31 Filed 2017-05-11
10-K 2016-12-31 Filed 2017-04-05
10-Q 2016-09-30 Filed 2016-11-02
10-Q 2016-06-30 Filed 2016-08-12
10-Q 2016-03-31 Filed 2016-05-13
10-K 2015-12-31 Filed 2016-04-13
8-K 2019-05-31 Officers, Exhibits
8-K 2018-10-25 Accountant, Exhibits
8-K 2018-01-10 Officers, Exhibits

HRDV 10Q Quarterly Report

Part I – Financial Information
Item 1. Financial Statements.
Note 1 – Summary of Significant Accounting Policies
Note 2 – Leases
Note 3 – Intangible Assets
Note 4 – Notes Payable
Note 5 – Related Party
Note 6 – Stockholders’ Deficiency
Note 7 – 2015 Incentive Stock Plan
Note 8 – Income Taxes
Note 9 – Business Segment Information
Note 10 – Litigation
Note 11 – Concentration
Note 12 – Subsequent Events
Part II - Other Information
Item 5. Other Information.
EX-31.1 ex31-1.htm
EX-32.1 ex32-1.htm

Health-Right Discoveries Earnings 2020-03-31

Balance SheetIncome StatementCash Flow
10.07.75.43.20.9-1.42015201620182020
Assets, Equity
3.22.41.50.7-0.2-1.02015201620182020
Rev, G Profit, Net Income
4.73.11.4-0.2-1.9-3.52015201620182020
Ops, Inv, Fin

10-Q 1 g081977_10q.htm 10-Q

 

 UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES AND EXCHANGE
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020

 

Commission file number: 333-206839

 

HEALTH-RIGHT DISCOVERIES, INC. 

(Exact name of registrant as specified in its charter)

 

Florida

 

45-3588650

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification No.)

 

18851 NE 29th Avenue, Suite 700, Aventura, Florida 33180 

(Address of Principal Executive Offices)

 

(305) 705-3247 

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

None

 

 

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ☐

Accelerated Filer ☐

Non-accelerated Filer ☐

Smaller reporting company ☒

 

Emerging growth company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

  

The number of shares outstanding of the registrant’s common stock, $0.001 par value, as of May 13, 2020 was 22,869,191 shares.

 

 

 
 

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements.

1

 

 

 

 

Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (unaudited)

1

 

 

 

 

Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (unaudited)

2

 

 

 

 

Consolidated Statements of Stockholders’ Deficiency for the three months ended March 31, 2020 and 2019 (unaudited)

3

 

 

 

 

Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 (unaudited)

4

 

 

 

 

Notes to Consolidated Financial Statements (unaudited)

5

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

19

 

 

 

Item 3.

Quantitative Disclosures About Market Risk.

23

 

 

 

Item 4.

Controls and Procedures.

24

 

 

 

PART II - OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings.

25

 

 

 

Item 1A.

Risk Factors.

25

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

25

 

 

 

Item 4.

Mine Safety Disclosures.

25

 

 

 

Item 5.

Other information.

25

 

 

 

Item 6.

Exhibits.

25

 

 

 

SIGNATURES

25

 

 i

 

 

PART I – FINANCIAL INFORMATION

 

Item 1.

Financial Statements.

 

HEALTH-RIGHT DISCOVERIES, INC. AND SUBSIDIARIES

 CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

 

March 31, 2020

 

 

December 31, 2019

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

Cash

 

$

2,067,432

 

 

$

2,242,013

 

Accounts receivable, net

 

 

40,416

 

 

 

52,281

 

Inventories

 

 

20,394

 

 

 

10,735

 

Prepaid and other assets

 

 

5,168

 

 

 

14,433

 

Total Current Assets

 

 

2,133,410

 

 

 

2,319,462

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

22,618

 

 

 

23,871

 

Right of use asset

 

 

22,935

 

 

 

25,001

 

Intangible assets, net

 

 

2,138,710

 

 

 

2,230,122

 

Goodwill

 

 

3,313,226

 

 

 

3,313,226

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

7,630,899

 

 

$

7,911,682

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,631,521

 

 

$

1,388,505

 

Current portion of right of use liability

 

 

8,291

 

 

 

8,040

 

Current portion - notes payable

 

 

2,500,000

 

 

 

2,500,000

 

Current portion - notes payable, net of discounts of $82,224 and $123,336 March 31, 2020 and December 31, 2019, respectively

 

 

5,222,276

 

 

 

5,181,164

 

Total Current Liabilities

 

 

9,362,088

 

 

 

9,077,709

 

 

 

 

 

 

 

 

 

 

LONG-TERM LIABILITIES:

 

 

 

 

 

 

 

 

Right of use liability, net of current portion

 

 

14,585

 

 

 

16,784

 

Deferred tax liability

 

 

212,882

 

 

 

364,882

 

Total Long-term Liabilities

 

 

227,467

 

 

 

381,666

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

$

9,589,555

 

 

$

9,459,375

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ DEFICIENCY

 

 

 

 

 

 

 

 

Preferred Stock, .001 par value, 5,000,000 shares authorized No shares issued and outstanding  March 31, 2020 and December 31, 2019, respectively

 

 

 

 

 

 

Common Stock, .001 par value, 100,000,000 shares authorized 22,869,191 shares issued and outstanding March 31, 2020 and December 31, 2019, respectively

 

 

22,869

 

 

 

22,869

 

Additional Paid in Capital

 

 

1,117,967

 

 

 

1,117,967

 

Accumulated Deficit

 

 

(3,099,492

)

 

 

(2,688,529

)

Total Stockholders’ Deficiency

 

 

(1,958,656

)

 

 

(1,547,693

)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

 

$

7,630,899

 

 

$

7,911,682

 

 

See accompanying notes to unaudited consolidated financial statements.

 1

 

 

HEALTH-RIGHT DISCOVERIES, INC. AND SUBSIDIARIES

 CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(Unaudited)

 

 

 

2020

 

 

2019

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

382,275

 

 

$

1,044,009

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

50,878

 

 

 

166,528

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

331,397

 

 

 

877,481

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

General and administrative

 

 

364,314

 

 

 

558,665

 

Amortization and depreciation

 

 

95,574

 

 

 

121,135

 

Total operating expenses

 

 

459,888

 

 

 

679,800

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

(128,491

)

 

 

197,681

 

 

 

 

 

 

 

 

 

 

Other Expenses

 

 

 

 

 

 

 

 

Interest expenses

 

 

434,472

 

 

 

240,984

 

Total other expenses

 

 

434,472

 

 

 

240,984

 

 

 

 

 

 

 

 

 

 

Loss before income tax benefit

 

 

(562,963

)

 

 

(43,303

)

 

 

 

 

 

 

 

 

 

Income tax benefit

 

 

152,000

 

 

 

11,136

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

$

(410,963

)

 

$

(32,167

)

 

 

 

 

 

 

 

 

 

Loss per common share

 

 

(0.02

)

 

 

(0.00

)

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding - basic and diluted

 

 

22,869,191

 

 

 

22,869,191

 

 

See accompanying notes to unaudited consolidated financial statements.

 2

 

 

 

HEALTH-RIGHT DISCOVERIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(Unaudited)

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

COMMON STOCK

 

 

Paid-In

 

 

Accumulated

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BALANCE – December 31, 2019

 

 

22,869,191

 

 

$

22,869

 

 

$

1,117,967

 

 

$

(2,688,529

)

 

$

(1,547,693

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss)

 

 

 

 

 

 

 

 

 

 

 

(410,963

)

 

 

(410,963

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BALANCE – March 31, 2020

 

 

22,869,191

 

 

$

22,869

 

 

$

1,117,967

 

 

$

(3,099,492

)

 

$

(1,958,656

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BALANCE – December 31, 2018

 

 

22,869,191

 

 

$

22,869

 

 

$

1,117,967

 

 

$

(1,209,611

)

 

$

(68,775

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adoption of ASU 2016-02

 

 

 

 

 

 

 

 

 

 

 

(18,254

)

 

 

(18,254

)

Net (loss)

 

 

 

 

 

 

 

 

 

 

 

(32,167

)

 

 

(32,167

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BALANCE – March 31, 2019

 

 

22,869,191

 

 

$

22,869

 

 

$

1,117,967

 

 

$

(1,260,032

)

 

$

(119,196

)

 

See accompanying notes to unaudited consolidated financial statements.

 

 3

 

 

 

HEALTH-RIGHT DISCOVERIES, INC. AND SUBSIDIARIES

 CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(Unaudited)

 

 

2020

 

 

2019

 

 

 

 

 

 

 

 

 

 

OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(410,963

)

 

$

(32,167

)

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

Depreciation expense

 

 

1,253

 

 

 

1,942

 

Amortization expenses

 

 

91,412

 

 

 

116,284

 

Right of use liability amortization

 

 

 

 

 

(775

)

Operating lease amortization

 

 

118

 

 

 

 

Non-cash interest

 

 

41,112

 

 

 

41,112

 

Deferred income tax benefit

 

 

(152,000

)

 

 

(11,137

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

11,865

 

 

 

28,641

 

Inventories

 

 

(9,659

)

 

 

11,427

 

Prepaid and other assets

 

 

9,265

 

 

 

(26,070

)

Accounts payable and accrued expenses

 

 

243,016

 

 

 

134,758

 

Accrued salary to related party

 

 

 

 

 

(50,000

)

NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES

 

 

(174,581

)

 

 

214,015

 

 

 

 

 

 

 

 

 

 

(DECREASE) INCREASE IN CASH

 

 

(174,581

)

 

 

214,015

 

 

 

 

 

 

 

 

 

 

CASH - BEGINNING OF PERIOD

 

 

2,242,013

 

 

 

2,149,738

 

 

 

 

 

 

 

 

 

 

CASH - END OF PERIOD

 

$

2,067,432

 

 

$

2,363,753

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

 Cash paid for interest

 

$

170,960

 

 

$

164,156

 

 

See accompanying notes to unaudited consolidated financial statements.

 4

 

 

HEALTH-RIGHT DISCOVERIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 – Summary of Significant Accounting Policies

 

Health-Right Discoveries, Inc. (“the Company”) was formed under the laws of the State of Florida on October 12, 2011 under the name Four Plex Partners, Inc. and subsequently changed its name to Health-Right Discoveries, Inc. on March 22, 2012. The Company’s primary business was to develop and market an innovative portfolio of both prescription nutritional, OTC monograph and natural products that primarily focus on factors relating to stress-induced conditions and diseases.

 

On September 29, 2017, pursuant to a Securities Purchase Agreement dated August 17, 2017, the Company acquired (the “Acquisition”) all the outstanding shares of Common Compounds, Inc., n/k/a CCI Billing, Inc. d/b/a Complete Claim Management (“CCI”) and EZPharmaRx, LLC n/k/a Script Connection, LLC (“SCLLC”). HRD, through its subsidiaries, CCI and SCLLC, along with licensed pharmaceutical wholesalers, offer and provide their respective services to physician practices that desire to prescribe and dispense certain pharmaceutical products and medications in the practice’s office to patients receiving treatment for work-related injuries (“In-Office Dispensing Program”).

 

CCI offers and provides administrative services and billing services to physician practices (each a “Practice” and collectively, the “Practices”) desiring to make certain over-the-counter products, including non-narcotic topical medications, (“OTC Products”), and certain prescription medications (“Prescription Medications”) available to patients in the physician practice’s office. Each participating Practice is responsible for obtaining and maintaining any necessary and appropriate licenses, permits, or other documentation required to order, receive, store, and dispense OTC Products or certain Prescription Medications in the Practice’s office in accordance with applicable federal and state law. Such services include, but are not limited to, assisting Practices with insurance claim processing, prior authorization, billing and collections, and recordkeeping. CCI offers its fee-based services to Practices participating in the In-Office Dispensing Program. CCI also provides billing and collection services on behalf of SCLLC in connection with SCLLC’s sales and distribution of OTC Products to Practices participating in the OTC Program.

 

SCLLC offers OTC Products to Practices that desire to make such products available to patients in the Practice’s office through participation in the OTC Program. SCLLC is not a compounding pharmacy, and neither CCI nor SCLLC is involved in creating topicals with compounding pharmacies.

 

SCLLC also assists the Practices in ordering Prescription Medications directly from licensed pharmaceutical wholesalers and oversees the sale and distribution of Prescription Medications to the Practices. SCLLC does not sell any Prescription Medications to Practices and does not profit from the sale of such medications.

 

The significant accounting policies of the Company were described in Note 2 to the audited consolidated financial statements included in the Company’s 2019 Annual Report on Form 10-K. There have been no significant changes in the Company’s significant accounting policies for the three months ended March 31, 2020.

 

Basis of Presentation

 

Principles of Consolidation 

 

The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned or controlled operating subsidiaries. All intercompany accounts and transactions have been eliminated.

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.  Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2019 Form 10-K for

 5

 

the year ended December 31, 2019. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2020 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future period. Certain prior period amounts have been reclassified to conform to the current presentation.

 

Use of Estimates

 

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company’s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from its estimates.

 

Cash and cash equivalents

 

The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents.

 

Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balances in various financial institutions. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2020 and December 31, 2019, $1,367,531 and $1,289,897 were in excess of the FDIC insured limit, respectively.

 

Accounts Receivable 

 

Accounts receivable are stated at the amount the Company expects to collect from customers. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. Management has rewarded an allowance for doubtful accounts in the amounts of $4,660 and $5,040 at March 31, 2020 and December 31, 2019 respectively. Management considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers was to deteriorate and adversely affecting their ability to make payments, additional allowances would be required.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements.

 

Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company’s accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition.

 6

 

 

CCI’s revenue results from the consulting services agreements, which included providing services to physicians for billing insurance companies. The Company has determined the performance obligations in these consulting service agreements relate to the satisfaction of billing the insurance company on behalf of the physicians. CCI remits billings to insurance companies on behalf of the physicians, collect the proceeds and remits an agreed upon percentage amount to the physician. The amounts reported as revenue are recorded net of amounts remitted. The Company follows Staff Accounting Bulletin (“SAB”) No. 104, which states that the revenue is not earned until the company has been paid by the insurance company at which time it becomes realized or realizable.

 

SCLLC’s revenue from the sale of products are recognized when the sale is consummated, and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.

 

The following tables disaggregate revenue by major source for the three months ended March 31, 2020 and 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31, 2020

 

 

Ancillary
Program

 

 

 

OTC and
Prescription
Medication

 

 

 

Corporate (1)

 

 

 

Total

 

Product Sales

 

$

 —

 

 

$

76,587

 

 

$

 

 

$

76,587

 

Consulting Services

 

 

305,688

 

 

 

 —

 

 

 

 —

 

 

 

305,688

 

Total Revenue

 

$

 305,688

 

 

$

 76,587

 

 

$

 —

 

 

$

 382,275

 


 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31, 2019

 

 

Ancillary
Program

 

 

 

OTC and
Prescription
Medication

 

 

 

Corporate (1)

 

 

 

Total

 

Product Sales

 

$

 —

 

 

$

221,123

 

 

$

 —

 

 

$

221,123

 

Consulting Services

 

 

822,886

 

 

 

 —

 

 

 

 —

 

 

 

822,886

 

Total Revenue

 

$

 822,886

 

 

$

 221,123

 

 

$

 —

 

 

$

1,044,009

 

 

(1)

The Company’s corporate group is non-revenue generating and supports our two reportable segments Ancillary Program and Prescription.

 

Inventories

 

Inventories, which consist of the Company’s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.

 

If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company’s statements of operations. Based on management’s estimate, there was no obsolete inventory at March 31, 2020 and December 31, 2019.

 

 7

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:

 

 

 

March 31,
2020

 

 

December 31,
2019

 

Machinery and equipment – 7 years

 

$

44,497

 

 

$

44,497

 

Accumulated depreciation

 

 

(21,879

)

 

 

(20,626

)

Total property and equipment

 

$

22,618

 

 

$

23,871

 

 

Intangible Assets

 

Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined.

 

Intangible assets are tested annually for impairment and are tested for impairment more frequently if events and circumstances indicate that the asset might be impaired. An impairment loss is recognized to the extent that the carrying amount of the asset group exceeds its fair value. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.

 

The Company calculates fair value of our intangible assets as the present value of estimated future cash flows the Company expects to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, The Company uses estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

 

During the third quarter 2019, the Company reviewed its customer lists and impaired approximately 50% of its value, or $1,061,200.

 

Goodwill

 

Goodwill is measured as the excess of consideration transferred and the net of the acquisition date fair value of assets acquired, and liabilities assumed in a business acquisition. In accordance with ASC 350, “Intangibles—Goodwill and Other,” goodwill and other intangible assets with indefinite lives are no longer subject to amortization but are tested for impairment annually or whenever events or changes in circumstances indicate that the asset might be impaired.

 

In January 2017, the FASB issued ASU 2017-04 that eliminates “step 2” from the goodwill impairment test. The Company made the election to early adopt ASU 2017-04 as of January 1, 2018 and the standard was applied on a prospective basis, as required. In accordance with ASC 350-25-35-3, “An entity may first assess qualitative factors, as described in paragraphs 350-20-35-3A through 35-3G, to determine whether it is necessary to perform the quantitative goodwill impairment test.” Management reviewed the following qualitative factors around its goodwill and believes that the fair value of its investment in the Company exceeds its carrying amount at March 31, 2020 and December 31, 2019. 

 

 8

 

The Company reviews the goodwill allocated to each of our reporting units for possible impairment annually as of December 31 and whenever events or changes in circumstances indicate carrying amount may not be recoverable.

 

When assessing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company performs a two-step impairment test. If the Company concludes otherwise, then no further action is taken. The Company also has the option to bypass the qualitative assessment and only perform a quantitative assessment, which is the first step of the two-step impairment test. In the two-step impairment test, the Company measures the recoverability of goodwill by comparing a reporting unit’s carrying amount, including goodwill, to the estimated fair value of the reporting unit.

 

In assessing the qualitative factors, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of the reporting unit. The identification of relevant events and circumstances, and how these may impact a reporting unit’s fair value or carrying amount involve significant judgments and assumptions. The judgment and assumptions include the identification of macroeconomic conditions, industry, and market considerations, cost factors, overall financial performance and share price trends, and making the assessment as to whether each relevant factor will impact the impairment test positively or negatively and the magnitude of any such impact.

 

The carrying amount of each reporting unit is determined based upon the assignment of our assets and liabilities, including existing goodwill and other intangible assets, to the identified reporting units. Where an acquisition benefits only one reporting unit, the Company allocates, as of the acquisition date, all goodwill for that acquisition to the reporting unit that will benefit. Where the Company has had an acquisition that benefited more than one reporting unit, The Company has assigned the goodwill to our reporting units as of the acquisition date such that the goodwill assigned to a reporting unit is the excess of the fair value of the acquired business, or portion thereof, to be included in that reporting unit over the fair value of the individual assets acquired and liabilities assumed that are assigned to the reporting unit.

 

If the carrying amount of a reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the impairment analysis to measure the amount of the impairment loss, by allocating the reporting unit’s fair value to its assets and liabilities other than goodwill, comparing the carrying amount of the goodwill to the resulting implied fair value of the goodwill, and recording an impairment charge for any excess.

 

Stock-based compensation

 

The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.

 

Income Taxes

 

The company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 9

 

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Earnings (Loss) Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.

 

Accounting for Business Combinations

 

In accordance with ASC Topic 805, “Business Combinations,” when accounting for business combinations we are required to recognize the assets acquired, liabilities assumed, contractual contingencies, non-controlling interests and contingent consideration at their fair value as of the acquisition date. These items are recorded on our unaudited consolidated balance sheets as of the respective acquisition dates based upon their estimated fair values at such dates. The results of operations of acquired businesses are included in the unaudited consolidated statements of operations since their respective acquisition dates.

 

The purchase price allocation process requires management to make significant estimates and assumptions with respect to intangible assets, estimated contingent consideration payments and/or pre-acquisition contingencies, all of which ultimately affect the fair value of goodwill established as of the acquisition date. Goodwill acquired in business combinations is assigned to the reporting unit(s) expected to benefit from the combination as of the acquisition date and is then subsequently tested for impairment at least annually. If the fair value of the net assets acquired exceeds the purchase price consideration, we record a gain on bargain purchase. However, in such a case, before the measurement period closes we perform a reassessment to reconfirm whether we have correctly identified all of the assets acquired and all of the liabilities assumed as of the acquisition date.

 

As part of our accounting for business combinations we are required to estimate the useful lives of identifiable intangible assets recognized separately from goodwill. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the acquired business. An intangible asset with a finite useful life shall be amortized; an intangible asset with an indefinite useful life shall not be amortized. We base the estimate of the useful life of an intangible asset on an analysis of all pertinent factors, in particular, all of the following factors with no one factor being more presumptive than the other:

 

 

The expected use of the asset.

 

 

The expected useful life of another asset or a group of assets to which the useful life of the intangible asset may relate.

 

 

Any legal, regulatory, or contractual provisions that may limit the useful life.

 

 

Our own historical experience in renewing or extending similar arrangements, consistent with our intended use of the asset, regardless of whether those arrangements have explicit renewal or extension provisions.

 

 

The effects of obsolescence, demand, competition, and other economic factors.

 

 

The level of maintenance expenditures required to obtain the expected future cash flows from the asset.

 10

 

 

If no legal, regulatory, contractual, competitive, economic, or other factors limit the useful life of an intangible asset to the reporting entity, the useful life of the asset shall be considered to be indefinite. The term indefinite does not mean the same as infinite or indeterminate. The useful life of an intangible asset is indefinite if that life extends beyond the foreseeable horizon—that is, there is no foreseeable limit on the period of time over which it is expected to contribute to the cash flows of the acquired business.

 

Although we believe the assumptions and estimates we have made have been reasonable and appropriate, they are based in part on historical experience and information obtained from the management of the acquired entity and are inherently uncertain. Examples of critical estimates in accounting for acquisitions include but are not limited to:

 

 

future expected cash flows from sales of products and services and related contracts and agreements;

 

 

discount and long-term growth rates; and

 

 

the estimated fair value of the acquisition-related contingent consideration, which is performed using a probability-weighted income approach based upon the forecasted achievement of post-acquisition pre-determined targets;

 

NOTE 2 – Leases

 

Adoption of ASC Topic 842, Leases

 

On January 1, 2019, the Company adopted ASC 842, Leases, using a modified retrospective method applied to all contracts as of January 1, 2019. Therefore, for reporting periods beginning after December 31, 2018, the financial statements are prepared in accordance with the current lease standard and the financial statements for all periods prior to January 1, 2019 are presented under the previous lease standard (“ASC 840”).

 

The Company determines if an arrangement is a lease, or contains a lease, when a contract is signed. The Company determines if a lease is an operating or financing lease and records a lease asset and a lease liability upon lease commencement.

 

The Company had operating leases for office space in Arkansas and South Carolina. The Company has no finance leases as of March 31, 2020. For office space, the Company has elected to combine the fixed payments to lease the asset and any fixed non-lease payments (such as maintenance or utility charges) when calculating the lease asset and lease liability. On July 29, 2019, the Company terminated its Arkansas lease effect October 31, 2019 in accordance with Section 8 of their First Amendment. On October 6, 2019, the Company entered into a new one year lease in Arkansas beginning on November 1, 2019 with monthly rent in the amount of $1,210 per month. The Company has a lease in Florida with a monthly rent of $80.

 

The Company recognizes lease expense on a straight-line basis over the lease term. Certain of our lease agreements include rent payments which are adjusted periodically for inflation. Any change in payments due to changes in inflation rates are recognized as variable lease expense as they are incurred. Variable lease expense also includes costs for property taxes, insurance and services provided by the lessor which are charged based on usage or performance.

 

Some leases have one or more options to renew, with renewal terms that can initially extend the lease term for various periods up to 2 years. The exercise of renewal options for office space and data centers is at the Company’s discretion and are included if they are reasonably certain to be exercised. As of March 31, 2020, the Company’s weighted-average remaining lease term for all leases was approximately 2.58 years.

 

When the rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rate as its discount rate to determine the present value of its lease payments. The incremental borrowing rates approximate the rate the Company would pay to borrow in the currency of the lease payments on a collateralized basis for the weighted-average life of the lease. As of March 31, 2020, the Company’s weighted-average discount rate was approximately 5.0%.

 

 11

 

 

The Company recognized the following related to leases in its Unaudited Consolidated Balance Sheets at March 31, 2020 and December 31, 2019:

 

Leases

 

Classification in Consolidated Balance Sheet

 

 

March 31,
2020

 

 

December 31,
2019

 

Operating lease assets

 

Right of use asset

 

 

$

22,935

 

 

$

25,001

 

Lease Liabilities:

 

 

 

 

 

 

 

 

 

 

 

Current operating lease liabilities

 

Right of use liability

 

 

$

8,291

 

 

$

8,040

 

Long-term operating lease liabilities

 

Right of use liability

 

 

 

14,585

 

 

 

16,784

 

Total operating lease liabilities

 

 

 

 

$

22,876

 

 

$

24,824

 

 

As of March 31, 2020, the operating lease liabilities will mature over the following periods: 

 

Remainder of 2020

 

$

6,850

 

2021

 

 

9,600

 

2022

 

 

8,000

 

2023

 

 

 

Total remaining lease payments

 

$

24,450

 

Less: Imputed interest

 

 

(1,574

)

Total capital lease liabilities

 

$

22,876

 

 

The Company recognized the following related to operating leases in its Unaudited Consolidated Statements of Operations at March 31, 2020 and 2019:

 

 

 

Classification in Unaudited

 

 

Three Months
Ended

March  31,

 

Leases

 

Consolidated Statements of Operations

 

 

2020

 

Lease expense

 

General and administrative and Information technology

 

 

$

2,372

 

Total lease expense

 

 

 

 

$

2,372

 

 

 

 

Classification in Unaudited

 

 

Three Months
Ended

March  31,

 

Leases

 

Consolidated Statements of Operations

 

 

2019

 

Lease expense

 

 

General and administrative and Information technology

 

 

$

15,484

 

Total lease expense

 

 

 

 

 

$

15,484

 

 

Supplemental cash flow information related to operating leases as of March 31, 2020 and 2019 are as follows: 

 

 

 

Three Months
Ended

March 31,

 

Leases

 

2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

Operating cash flow from operating leases

 

$

2,372

 

Right-of-use assets obtained in exchange for lease obligations:

 

 

 

 

Operating Leases

 

$

 

 

12

 

 

 

 

Three Months

 

 

 

Ended
March 31,

 

Leases

 

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

Operating cash flow from operating leases

 

$

15,484

 

Right-of-use assets obtained in exchange for lease obligations:

 

 

 

 

Operating Leases

 

$

 

 

“Operating lease amortization” presented in the operating activities section of the Unaudited Consolidated Statements of Cash Flows reflects the portion of the operating lease expense that amortized the operating lease asset.

  

 NOTE 3 – Intangible Assets

 

Amortizing
Intangible Assets

 

Estimates
Useful Life

 

 

Gross Carrying
Amount
March 31,
2020

 

 

Gross Carrying
Amount
December 31,

2019

 

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

 

8 years

 

 

$

    1,326,500

 

 

$

    1,326,500

 

Tradenames

 

 

15 years

 

 

 

377,000

 

 

 

377,000

 

IP Technologies

 

 

10 years

 

 

 

819,000

 

 

 

819,000

 

Non-compete

 

 

5 years

 

 

 

464,000

 

 

 

464,000

 

 

 

 

 

 

 

 

2,986,500

 

 

 

2,986,500

 

Less: Accumulated Amortization

 

 

 

 

 

 

(847,790

 

 

(756,378

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

    2,138,710

 

 

$

         2,230,122

 

 

The amortization expense related to the intangible assets was $91,412 and $116,284 for the three months ended March 31, 2020 and 2019 respectively. During the third quarter 2019, the Company reviewed its customer lists and impaired approximately 50% of its value, or $1,061,200.

 

The valuation of the assets acquired and liabilities assumed in connection with this acquisition was based on fair values at the acquisition date. The assets purchased and liabilities assumed for these acquisitions have been reflected in the accompanying consolidated balance sheets.

 

NOTE 4 – Notes payable

 

The Company obtained a secured convertible note with a lender for $5 million, interest is payable monthly, at 12.75% per annum, the note matures on September 29, 2020. The note can be converted at any time in whole or in part at $0.44 per share. In addition, the lender received 3,584,279 shares of common stock valued at $0.10 per share along with a 2% original issue discount. The total amount of the discount is $493,345. The Company had incurred $34,917 in loan costs. Both the discount and loan costs are presented as a discount to the note payable. The Company recorded $154,500 and $150,000 of payment-in-kind interest which was added to the note as of December 31, 2019 and 2018, respectively. The note is collateralized by substantially all the assets of the Company.

 

 

13

 

 

The Company, as part of consideration for the purchase of CCI and SCLLC, issued a $2.5 million promissory note to the seller. The note is non-interest bearing with five annual payments of $500,000 (subject to adjustment to $377,400 if the business of CCI and SCLLC does not meet certain financial targets in 2017 and 2018) and matures on September 30, 2022. Interest has been imputed at 12.75% per annum. The note is in default as of September 30, 2018 due to the Company not making the required principal payment (see Note 10).

 

The Company has expensed default interest (17% per annum) in the amounts of $105,959 and $104,795 as of three months March 31, 2020 and 2019, respectively. Upon each annual payment date (each, a “Due Date”), the holder may elect to convert the annual installment of the principal amount due into shares of common stock at a conversion price equal to 50% of “fair market value,” which is defined as the average closing price for the shares on the principal market on which they are traded during the thirty (30) trading days prior to the applicable Due Date, provided, further, that (a) the conversion price shall not be lower than $2.00 per share, subject to adjustment for stock splits, stock dividends and similar recapitalization events; and (b) in the event such conversion price as so adjusted is lower than $2.00 per share, the installment payable upon such Due Date may not be converted into shares without written agreement between the Company and the seller. 

 

 

 

March 31,
2020

 

 

December 31,
2019

 

 

 

 

 

 

 

 

 

 

Note payable – monthly interest, 12.75% per annum, matures on September 29, 2020

 

$

5,304,500

 

 

$

5,304,500

 

Less discounts

 

 

(82,224

)

 

 

(123,336

)

 

 

 

 

 

 

 

 

 

Note payable – monthly interest, 17.00% per annum, matures on September 30, 2022 (The loan is currently in default and currently payable.)

 

 

2,500,000

 

 

 

2,500,000

 

Less discounts

 

 

 

 

 

 

Subtotal

 

 

7,722,276

 

 

 

7,681,164

 

Less: current portion

 

 

7,722,276

 

 

 

7,681,164

 

Long-term portion

 

$

 

 

$

 

 

Principal payments on the above notes mature as follows:                

 

Three months ending
March 31, 2020:

 

 

 

2020

 

$

8,334,508

 

2021

 

 

 

2023

 

 

 

2023

 

 

 

2024

 

 

 

Thereafter

 

$

8,334,508

 

 

NOTE 5 – Related Party

 

On January 10, 2018, the Company entered into employment agreement with David Hopkins, its President, effective as of January 1, 2018. Pursuant to the employment agreement, Mr. Hopkins assumed the additional position of Chief Executive Officer of the Company. The employment agreement is for an initial term of three (3) and automatically renews for additional three (3) year periods, provided that the Company achieves Adjusted EBITDA (as defined) of $3,500,000 for any calendar year during the initial term and any renewal term.

  

The employment agreement provides for an initial base salary of $175,000. In the event in any calendar year during the initial term or any renewal term, HRD achieves Adjusted EBITDA of $3,500,000, Mr. Hopkins’ annual base salary shall automatically increase to $250,000 and in the event in any calendar year during the initial term or any renewal term, the Company achieves Adjusted EBITDA of $5,000,000, his annual base salary shall automatically increase to $325,000. Mr. Hopkins will also receive a $600 per month car allowance while the employment agreement is in effect.

14

 

In addition to the foregoing, pursuant to the employment agreement, Mr. Hopkins was granted an option to purchase 525,000 shares of HRD common stock under the Company’s 2015 Stock Incentive Plan at an exercise price of $0.35 per share. The option vests in six equal semi-annual installments commencing June 30, 2018, expires ten (10) years from the date of grant and is otherwise subject to the terms of the Incentive Plan. 

 

In consideration for David Hopkins, the Company’s Chief Executive Officer and President, assuming the additional duties of President of the Company’s two subsidiaries, CCI and SCLLC, on May 31, 2019, the Company entered into an amended and restated employment agreement with Mr. Hopkins, effective as of April 15, 2019 (the “Effective Date”), which superseded the January 2018 employment agreement between the Company and Mr. Hopkins. The amended and restated employment agreement is for an initial term of three (3) years from the Effective Date and automatically renews for additional three (3) year periods, provided that the subsidiaries achieve combined Adjusted EBITDA (as determined by the Company’s accountants from the subsidiaries’ financial statements used in preparing the Company’s audited financial statements) of $3,000,000 for any calendar year during the initial term and any renewal term.

 

The amended and restated employment agreement provides for an initial base salary of $250,000. In the event in any calendar year during the initial term or any renewal term, the Subsidiaries achieve combined Adjusted EBITDA (as determined by the Company’s accountants from the subsidiaries’ financial statements used in preparing the Company’s audited financial statements) of $3,000,000, Mr. Hopkins’ annual base salary shall automatically increase to $300,000 and in the event in any calendar year during the initial term or any renewal term, the subsidiaries achieve combined Adjusted EBITDA (as determined by the Company’s accountants from the subsidiaries’ financial statements used in preparing the Company’s audited financial statements) of $3,500,000, his annual base salary shall automatically increase to $350,000. Mr. Hopkins will also receive a $600 per month car allowance while the amended and restated employment agreement is in effect.

 

The Company has a secured convertible note with a lender for $5 million (See Note 4).

 

NOTE 6 – Stockholders’ Deficiency

 

The Company has authorized 100,000,000 shares of common stock $.001 par value and 5,000,000 shares of preferred stock $.001 par value.

 

NOTE 7 – 2015 Incentive Stock Plan

 

Our 2015 Incentive Stock Plan (the “Incentive Plan”) provides for equity incentives to be granted to our employees, executive officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the Incentive Plan, restricted stock awards, other stock based awards, or any combination of the foregoing. The Incentive Plan is administered by the board of directors. 3,000,000 shares of our common stock are reserved for issuance pursuant to the exercise of awards under the Incentive Plan. The number of shares so reserved automatically adjusts upward on January 1 of each year, so that the number of shares covered by the Incentive Plan is equal to 15% of our issued and outstanding common stock. As of March 31, 2020 options to purchase 1,087,500 shares at an exercise price of $0.35 per share have been granted and are outstanding under the Incentive Plan.

 

NOTE 8 – Income Taxes

 

Income tax (provision) benefit for the three months ended March 31, 2020 and 2019 was $152,000 and $11,136, respectively. The effective tax rates for the periods were 27%   respectively. The 2018 tax rate reflects the enactment of the Tax Cuts and Jobs Act of 2017 (the “Act”) which made significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. 

 

 As of March 31, 2020, the Company has approximately $1,350,000 of federal and state net operating loss carryovers (“NOLs”) which carry forward indefinitely.

  

15

 

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.  Based on the assessment, management has established $0 valuation allowance against the deferred tax asset relating to NOLs because it is more likely than not that all of the deferred tax asset will be realized.

 

The Company files U.S. federal and state of Florida and Arkansas tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2016. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

 

NOTE 9 – Business Segment Information

 

The Company has two reportable segments (billing services and OTC and prescription medication) supported by a corporate group which conducts activities that are non-segment specific. The following table present selected financial information about the Company’s reportable segments for the three months ended March 31, 2020 and 2019.

 

For the three months

ended March 31, 2020

 

 

Consolidated

 

 

Billing
Services

 

OTC and
Prescription
Medication

 

 

Corporate

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

382,275

 

 

$

305,688

 

$

76,587

 

$

 

Cost of Revenue

 

 

50,878

 

 

 

 

 

50,878

 

 

 

Long-lived assets

 

 

5,497,489

 

 

 

4,962,810

 

 

534,679

 

 

 

Income (loss) before income tax

 

 

(562,963

)

 

 

175,449

 

 

23,045

 

 

(761,457

)

Identifiable assets

 

 

2,184,263

 

 

 

1,649,584

 

 

534,679

 

 

 

Depreciation and amortization

 

 

95,574

 

 

 

71,680

 

 

23,894

 

 

 

 

 

For the three months

ended March 31, 2019

 

 

Consolidated

 

 

Billing Services

 

OTC and
Prescription
Medication

 

 

Corporate

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

1,044,009

 

 

$

822,886

 

$

221,123

 

$

 

Cost of Revenue

 

 

166,528

 

 

 

 

 

166,528

 

 

 

Long-lived assets

 

 

7,139,768

 

 

 

5,407,637

 

 

1,732,131

 

 

 

Income (loss) before income tax

 

 

(43,303

)

 

 

519,088

 

 

39,814

 

 

(602,205

)

Identifiable assets

 

 

3,826,542

 

 

 

2,922,717

 

 

903,825

 

 

 

Depreciation and amortization

 

 

121,135

 

 

 

91,337

 

 

29,798

 

 

 

 

NOTE 10 – Litigation

 

In August 2018, we were served with a complaint (which was amended in September 2018 to include David Hopkins, our CEO, as a defendant), filed in Miami-Dade County, Florida Circuit Court by the seller of CCI and SCLLC. In the complaint, the seller alleges breach of contract and fraud in that we allegedly failed to pay him excess working capital as of the closing of the acquisition of approximately $381,000 and failed to reimburse him for certain credit card expenses. We believe that the seller’s claims are without merit, as his calculation of working capital does not follow the methodology provided for in the Securities Purchase Agreement for the transaction and that in fact, there was a working capital shortfall at closing of approximately $725,000 (for which we demanded payment in June 2018). Moreover, the seller has refused to submit the working capital dispute to the resolution process provided for in the Securities Purchase Agreement. We have answered the complaint denying the seller’s claims and have filed counterclaims against the seller for the sums we believe are do us for the working capital shortfall and for damages arising from seller’s breach of contract, breach of good faith and fair dealing, fraud in the inducement, indemnification obligations under the Securities Purchase Agreement and violation of his non-competition and non-solicitation agreement with the Company.

 

 

16

 

 

The parties have engaged in discovery, and we believe that the information obtained thus far supports our claims and refutes the seller’s claims.  On November 18, 2019, the seller filed a motion, asking the court to stay the case temporarily because he believed he was the target of a parallel federal criminal investigation related to facts at issue in the case.  On December 11, 2019, the court granted his motion and stayed the case for 120 days.

 

The stay issued by the court on December 11, 2019 expired on April 13, 2020.  The seller has again moved to stay the case, claiming that the instant proceedings overlap with an ongoing federal criminal investigation in which he believes he is a target.  Health-Right and Mr. Hopkins have opposed Burroughs' second motion to stay.  Health-Right and Mr. Hopkins also recently filed an amended counterclaim to add claims against the seller for breach of the non-compete and non-solicitation provisions of the Securities Purchase Agreement.  The seller has not yet responded to the amended counterclaim.  The Seller also filed a second amended complaint against Health-Right and Mr. Hopkins, which Health-Right and Mr. Hopkins have moved to dismiss as legally insufficient.

 

In April 2018, Stephen Andrews, the former CEO of CCI, filed a wrongful termination arbitration claim seeking recovery in the amount in excess of $500,000. In addition to raising defenses, the Company has filed a counterclaim alleging violation of non-disclosure/non-compete agreements by Mr. Andrews as well as claims for breach of a non-solicitation agreement, breach of the employee manual and injunctive relief. The final arbitration hearing was scheduled for January 2020.  However, Andrews moved for a stay of the arbitration on November 20, 2019 based on his belief that he is the target of a parallel federal criminal grand jury investigation.  The arbitrator granted the stay on December 17, 2019 and the final arbitration hearing was postponed indefinitely.

 

NOTE 11 – Concentration

 

The Company offers physicians and medical clinics an ancillary program to treat their patients with topical prescription medicine to manage pain. The program is designed for patients with work related injuries managed under worker compensation claims. The program both delivers the topical medicine to the care provider for sale to the patient, as well as providing the care provider with insurance claim processing services on behalf of the patient.

 

Accounts Receivable Concentration

 

 

 

At March 31, 2020

 

 

At December 31, 2019

 

 

 

 

 

 

 

 

Number of customers over 10%

 

 

5

 

 

 

6

 

Percentage of accounts receivable

 

 

13%, 15%, 16%, 29%, 38

%

 

 

10%, 12%, 13%, 13%, 15%, 18

%

 

We have two vendors who both represent 100% of purchased products that are sold for first quarter 2020 and 2019.

 

For the three months ended March 31, 2020, the Company had three clinics that represented 10%, 10%, and 16% of total revenue.  For the three months ended March 31, 2019, the Company had no clinics that represented more than 10% of total revenue. 

 

NOTE 12 – Subsequent Events

 

The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were the following subsequent events requiring adjustment to or disclosure in the financial statements.

 

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

 

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020. 

 

17

 

 

The Company has been approved for funds under the Paycheck Protection Program after the period end in the amount of $117,713. The application for these funds requires the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further requires the Company to take into account our current business activity and our ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the Company having initially qualified for the loan and qualifying for the forgiveness of such loan based on our future adherence to the forgiveness criteria.

 

18

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Unless the context otherwise requires, references in this report to “HRD,” “Health-Right,” “the Company,” “we,” “our“ and “us” refers to Health-Right Discoveries, Inc. and its subsidiaries.

 

Forward-Looking Statements

 

Certain statements made in this report are “forward-looking statements” regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein particularly in view of the current state of our operations, the inclusion of such information should not be regarded as a statement by us or any other person that our objectives and plans will be achieved. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

Historical Background

 

Business Overview

 

Health-Right was founded as a natural biotech company that sought to combine science and nutrition to develop branded ingredients, formulations and products that seek to provide a better quality of life for consumers who primarily suffer from stress-induced viruses and diseases. The Company developed a formulation platform by utilizing and scientifically combining various natural ingredients to help positively influence the interrelationship between stress and the immune system. The Company initially applied the formulation platform to Advanced H-Plex Defense Formula 11, its first product (“H-Plex Defense”), an all-natural dietary supplement whose formulation sought to address less than optimal nutrition and nutritional deficiencies to aid persons afflicted with Herpes Simplex Virus 1. Despite test marketing H-Plex Defense through the end of 2014 and positive customer feedback, HRD was unable to raise sufficient capital to complete development of and commercialize H-Plex Defense.

 

Accordingly, during 2016, the Company shifted its focus to identifying and exploring various opportunities for growth and revenue generation through the acquisition of other products, technologies or companies in the natural biotech, healthcare, nutraceutical and related fields.

 

Business Overview

 

On September 29, 2017, pursuant to a Securities Purchase Agreement dated August 17, 2017, the Company acquired (the “Acquisition”) all the outstanding shares of Common Compounds, Inc., n/k/a CCI Billing, Inc. d/b/a Complete Claim Management (“CCI”) and EZPharmaRx, LLC n/k/a Script Connection, LLC (“SCLLC”). HRD, through its subsidiaries, CCI and SCLLC, along with licensed pharmaceutical wholesalers, offer and provide their respective services to physician practices that desire to prescribe and dispense certain pharmaceutical products and medications in the practice’s office to patients receiving treatment for work-related injuries (“In-Office Dispensing Services”).

 

19

 

 

CCI offers and provides administrative services and billing services to physician practices (each a “Practice” and collectively, the “Practices”) desiring to make certain over-the-counter products, including non-narcotic topical medications, (“OTC Products”) and certain prescription medications (“Prescription Medications”) available to patients in the physician practice’s office. Each participating Practice is responsible for obtaining and maintaining any necessary and appropriate licenses, permits, or other documentation required to order, receive, store, and dispense OTC Products or Prescription Medications in the Practice’s office in accordance with applicable federal and state law. Such services include, but are not limited to, assisting Practices with insurance claim processing, prior authorization, billing and collections, and recordkeeping. CCI offers its fee-based services to Practices participating in the In-Office Dispensing Program. CCI also provides billing and collection services on behalf of SCLLC in connection with SCLLC’s sales and distribution of OTC Products to Practices participating in the OTC Program.

 

SCLLC offers OTC Products to Practices that desire to make such products available to patients in the Practice’s office through participation in the OTC Program. SCLLC is not a compounding pharmacy, and neither CCI nor SCLLC is involved in creating topicals with compounding pharmacies.

 

SCLLC also assists the Practices in ordering Prescription Medications directly from licensed pharmaceutical wholesalers and oversees the sale and distribution of Prescription Medications to the Practices. SCLLC does not sell any Prescription Medications to Practices and does not profit from the sale of such medications.

 

Since completion of the Acquisition, the Company has focused on restructuring CCI’s and SCLLC’s business operations and refining their business model to improve efficiency and profitability, as well as expanding those operations.

 

Potential Effects of the Coronavirus Outbreak

 

The adverse public health developments and economic effects of the COVID -19 outbreak could adversely affect the Company’s customers and suppliers as a result of quarantines, facility closures and logistics restrictions imposed in connection with the outbreak. More broadly, the outbreak could potentially lead to an extended economic downturn, which would likely decrease spending, adversely affect demand for our products and services and harm our business, results of operations and financial condition. The Company cannot accurately predict the effect the Coronavirus outbreak will have on the Company.

 

Corporate Information

 

The Company was incorporated in the state of Florida on October 11, 2011 under the name “Four Plex Partners, Inc.” and changed its name to “Health-Right Discoveries, Inc.” on March 22, 2012.

 

Our executive offices are located at 18851 NE 29th Avenue, Suite 700, Aventura, Florida 33180 and our telephone number is (305) 705-3247. Our corporate website is www.health-right.com. Information appearing on our corporate website is not part of this report.

 

Results of Operations

 

Three months ended March 31, 2020 compared to three months ended March 31, 2019

 

For the three months ended March 31, 2020, we had revenues of $382,275, as compared to $1,044,009 for the three months ended March 31, 2019. Cost of revenue was $50,878 for the 2020 quarter, as compared to $166,528 for the 2019 quarter. The decline in revenues and cost of revenue from 2019 to 2020 reflects the final restructuring phase of previous business operations and refinement of the business model. The Company was also affected by loss of revenue from a key state from which CCI previously generated significant business. Moreover, the COVID-19 outbreak appears to have had an adverse impact commencing in March 2020 and management is closely assessing operations as the country begins to reopen.

  

General and administrative costs were $364,314 for the three months ended March 31, 2020, as compared to $558,665 for the three months ended March 31, 2019, with the decrease similarly attributable to our restructuring effort and a reduction in legal fees as a result of the stay orders in effect with respect to pending litigation. Interest expense for the 2020 quarter increased approximately 80.3% to $434,472 from $240,984 for the 2019 quarter. Interest in both periods largely reflects interest on the issuance of notes to the seller and the lender on September 29, 2017, in connection with completing and financing the Acquisition.  As a result of the technical default under such notes as a result of the dispute between the seller and the Company, such notes now accrue interest for financial statement purposes at the higher default rate.

 

20

 

 

During the three months ended March 31, 2020, the Company incurred amortization and depreciation of $95,574 related to its intangible assets and property and equipment, as compared to amortization and depreciation of $121,135 during the 2019 quarter.

 

Income tax benefit for the three months ended March 31, 2020 was $152,000, as compared to income tax benefit of $11,136 for the three months ended March 31, 2019.

 

The Company had a net loss for the three months ended March 31, 2020 of $410,963, as compared to a net loss of $32,167 for the three months ended March 31, 2019. The increase in net loss from 2019 to 2020, was largely attributable to the loss of revenue from a key state where CCI previously conducted significant business. Also the COVID-19 outbreak appears to have had an adverse impact commencing in March 2020. Management is closely assessing operations as the country begins to reopen.

 

Liquidity and Capital Resources

 

As of March 31, 2020, total assets were $7,630,899, as compared to $7,911,682 on December 31, 2019, with the decrease being attributable to the amortization of intangible assets and by a decrease in additional cash on hand from operations. Total current liabilities as of March 31, 2020 were $9,362,088, as compared to $9,077,709 as of December 31, 2019. As of March 31, 2020 and December 31, 2019, the Company had long-term liabilities of $227,467 and $381,666, respectively.

 

After closing of the Acquisition in September 2017, a dispute arose between the seller of CCI and SCLLC and the Company, (which is the subject of pending litigation). Such dispute relates to amounts the Company believes are due it from the seller (a) as a result of a shortfall in working capital at closing of the Acquisition; and (b) pursuant to seller’s indemnification obligations under the Securities Purchase Agreement and violation of his non-competition agreement with the Company. We are seeking to set off certain of the sums we believe are due us against principal and interest payments under the CCI Note, and as such may be deemed to be technically in default thereunder, resulting in a reclassification of certain long-term liabilities to current liabilities effective December 31, 2018, pending resolution of the dispute.

 

Net cash used in operating activities was to $174,581 for the three months ended March 31, 2020, as compared to net cash provided by operating activities of $214,015 for the three months ended March 31, 2019, reflecting the restructuring and refinement of our operations.

 

The Company believes that its existing capital resources when combined with anticipated cash flow from operations, will allow it to fund its operations for 2020, assuming, however, that the Company is able to refinance or otherwise extend and/or modify the GPB Note prior to its maturity in September 2020. There can be no assurance that we will be able to do so or secure financing, when required, on commercially reasonable terms. Any such additional financing may dilute the interests of existing shareholders. The absence of additional financing, when needed, could substantially harm the Company, its business, results of operations and financial condition.

 

Critical Accounting Policies

 

Revenue Recognition

 

As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company’s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company’s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.

 

21

 

 

CCI’s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.

 

SCLLC’s revenue from the sale of products are recognized when the sale is consummated, and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.

 

Accounting for Leases

 

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASC 842”) that amends the accounting guidance on leases for both lessees and lessors. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve (12) months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The FASB also subsequently issued amendments to the standard, including providing an additional and optional transition method to adopt the new standard, described below, as well as certain practical expedients related to land easements and lessor accounting. The amendments in this accounting standard update are effective for the Company on January 1, 2019, with early adoption permitted. The Company adopted this accounting standard update effective January 1, 2019.

 

22

 

  

Intangible Assets

 

Intangible assets consist primarily of the Tradenames, IP Technologies, Customer list, and a Non-compete agreement resulting from the acquisition referred to in Note 3. These intangible assets have finite lives and are amortized over the periods in which they provide benefit. The Company assesses the impairment of long-lived assets, including identifiable intangible assets subject to amortization, whenever significant events or significant changes in circumstances indicate the carrying value may not be recoverable. Intangible assets with indefinite lives, are subject to impairment testing in accordance with accounting standards governing such on an annual basis, or more frequently if an event or change in circumstances indicates that the fair value of a reporting unit has been reduced below its carrying value. See Note 3 to the unaudited consolidated financial statements for disclosure on intangible assets.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates included deferred revenue, costs incurred related to deferred revenue, the useful lives of property and equipment, the useful lives of intangible assets and accounting for the business combination.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740.

 

ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3.

Quantitative Disclosures About Market Risks.

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

23

 

 

Item 4.

Controls and Procedures.

 

Management’s Report on Disclosure Controls and Procedures

 

Our President and Chief Executive Officer, as our principal Executive, Financial and Accounting Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, as of March 31, 2020, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms adopted by the Securities and Exchange Commission (the “SEC”), including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our President, as our Principal Executive, Financial and Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our President has concluded that as of March 31, 2020, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in Item 9A(b) of our Annual Report on Form 10-K for the year ended December 31, 2019.

 

Our President and Chief Executive Officer, as our principal Executive, Financial and Accounting Officer, does not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officer has determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

24

 

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings.

 

For an update to the legal proceedings described in response to “Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2019, see “Note 10 – Litigation” in the Notes to the Unaudited Consolidated Financial Statements included in “Item 1. Financial Statements” in this report. In addition, from time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business.

 

Item 1A.

Risk Factors.

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 4.

Mine Safety Disclosures.

 

Not applicable.

 

Item 5.

Other Information.

 

None.

 

Item 6.

Exhibits.

 

Exhibit
Number

 

Description of Exhibit

31.1

 

Section 302 Certification

32.1

 

Section 906 Certification

101.INS

 

XBRL Instance Document

101.SCH

 

XBRL Taxonomy Extension Schema Document

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

HEALTH-RIGHT DISCOVERIES, INC.

 

 

Dated:  May 13, 2020

By:

/s/ David Hopkins

 

 

David Hopkins, President and
Chief Executive Officer

 

 

(Principal Executive, Financial and Accounting Officer)

 

25